FGFR-4 Monoclonal Antibody

The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of this gene, compared to members 1-3, encompasses 18 exons rather than 19 or 20. Although alternative splicing has been observed, there is no evidence that the C-terminal half of the IgII

Introducing the FGFR-4 Monoclonal Antibody, a cutting-edge pharmaceutical innovation designed to target and inhibit the Fibroblast Growth Factor Receptor 4 (FGFR-4) protein. This meticulously developed antibody showcases exceptional specificity and affinity towards FGFR-4, making it an invaluable tool in the field of molecular biology and therapeutic research.

The FGFR-4 Monoclonal Antibody is meticulously engineered using state-of-the-art techniques, ensuring its high purity and stability. Its superior quality guarantees reliable and reproducible results, making it an indispensable asset for scientists and researchers alike.

This antibody's remarkable ability to selectively bind to FGFR-4 enables it to effectively block the receptor's activation, thereby impeding downstream signaling pathways associated with cell proliferation, differentiation, and survival. By doing so, it offers immense potential for therapeutic interventions in various diseases, including cancer, where FGFR-4 dysregulation plays a pivotal role.

Furthermore, the FGFR-4 Monoclonal Antibody exhibits exceptional versatility, allowing for a wide range of applications. Its compatibility with various experimental techniques, such as immunohistochemistry, immunofluorescence, and Western blotting, empowers researchers to explore and elucidate the intricate mechanisms underlying FGFR-4-related pathologies.

With its robust performance and unparalleled specificity, the FGFR-4 Monoclonal Antibody represents a breakthrough in the field of molecular biology and therapeutic research. Its potential to revolutionize the understanding and treatment of FGFR-4-associated diseases is truly remarkable. Embrace the power of precision and reliability with the FGFR-4 Monoclonal Antibody, and unlock new frontiers in scientific exploration and medical advancements.